OBI Pharma bags FDA Orphan Drug Designation for cancer drug, OBI-999
Category: #health  By Saipriya Iyer  Date: 2019-12-27
  • share
  • Twitter
  • Facebook
  • LinkedIn

OBI Pharma bags FDA Orphan Drug Designation for cancer drug, OBI-999

Taiwan-based biopharmaceutical firm, OBI Pharma, Inc. has reportedly been granted the Orphan Drug Designation by the U.S. FDA (Food and Drug Administration) for Pancreatic Cancer treatment OBI-999. Sources claim that the Phase 1/2 clinical trial of OBI-999 was commenced at the University of Texas M.D. Anderson Cancer Center in patients with locally advanced or metastatic solid tumors, including pancreatic, colorectal, gastric, and esophageal cancers.

The trial aimed at verifying the preliminary efficacy and safety of OBI-999 in patient who are already diagnosed with per protocol tumor types, including pancreatic and colorectal, cancers of high unmet clinical needs.

According to a statement, Tillman Pearce, CMO, OBI Pharma, said that their firm is thrilled about the potential value of OBI-999 that it would provide to patients with pancreatic cancer, given to the high potency observed using OBI-999 in pancreatic cancer xenograft models.

Pancreatic cancer usually originates in the endocrine or exocrine pancreatic cells and is likely to be caused by smoking, poor diet, and genetic factors. It is a deadly disease that reportedly affects around 69,839 people in the U.S. with a survival rate of only 8.5% at five years. Its treatment options are limited to surgical resection for patients with early stages of pancreatic cancer and may only have a five-year survival rate of up to 34.3%.

Meanwhile, as a potential treatment, OBI-999 is a first-in-class ADC (Antibody Drug Conjugate) with exclusive linker technology that offers consistent DAR (Drug-to-Antibody ratio) for cancer treatment that is based on Globo H.

The drug makes use of Globo H antibody to focus on cancer cells the possess higher Globo H expression. By letting out a small molecule chemotherapeutic drug through the specificity of the antibody, OBI-999 directly deploys cytotoxic therapy at the targeted cancer cells.

Source Credit: https://finance.yahoo.com/news/obi-pharma-granted-fda-orphan-100000544.html?guccounter=1



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

Alibaba to acquire 10% stake in Yunda from controlling shareholders
Alibaba to acquire 10% stake in Yunda from controlling shareholders
By Saipriya Iyer

Alibaba Group Holding Limited, a Chinese multinational technology company, is reportedly planning to purchase nearly 10% stakes in Yunda Holding Co Ltd. This acquisition marks the e-Commerce company’s 5th investm...

Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
Amazon warehouse workers plan walkout in NYC due to COVID-19 fear
By Saipriya Iyer

A group of Amazon workers at its New York City facility reportedly held a walk out and went on strike over the lack of safety protocols by the e-Commerce giant, amid COVID-19 pandemic concerns. These workers further de...

Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
Regeneron-Sanofi announce 1st patient for clinical study outside U.S.
By Saipriya Iyer

Regeneron Pharmaceuticals, Inc. & Sanofi have recently announced the 1st patient to be treated in the COVID-19 clinical program, outside of the United States. The study, which is anticipated to enroll nearly 300 pa...